According to a study published online in Thorax, tobacco treatments such as nicotine replacement therapy and behavioral support therapy can assist dual users of traditional cigarettes and e-cigarettes in quitting smoking.
Dr. Brendan T. Hayden, from the University of Washington School of Medicine, evaluated whether formal tobacco treatment (pharmacotherapy and/or behavioral support) enhanced smoking cessation among individuals who use both cigarettes and e-cigarettes. The analysis included 111,823 outpatients who visited tertiary care medical centers between June 2018 and June 2020.
During the course of the study, researchers found that dual use of cigarettes and e-cigarettes significantly increased every six months (0.8%, 1.1%, 1.8%, and 2.3% respectively). At the 12-month mark, e-cigarette users had a higher quit rate (20.8%) compared to non-smokers (16.8%; adjusted relative risk was 1.354). Individuals receiving tobacco treatment had a higher quit rate at 12 months (29.1%) compared to non-smokers (19.6%; adjusted relative risk was 1.238).
In a statement, Hayden mentioned that although current guidelines do not recommend quitting smoking, they have indeed found that traditional tobacco treatments approved by the US Food and Drug Administration, such as nicotine replacement therapy and behavioral support therapy, can help those who use these products quit smoking.
Click to see the original research article.
Sorry, as an AI language model, I cannot provide a translation without the text to be translated. Please provide the text.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
